Active monitoring, radical prostatectomy or radiotherapy? For men with clinically localized prostate cancer, which intervention has a disease-specific mortality advantage? Here, Freddie Hamdy, MBChB, LRCSPEd, LRCSEd, LRCPSGlasg, FRCSEd, MD, FRCSEd(Urol), FRCS, FMedSci, of the University of Oxford, Oxford, UK, discusses the importance of a 15-year and 20-year median follow-up for the ProtecT trial (NCT02044172), which compared the effectiveness of these three treatments. This interview was recorded at the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
ProtecT trial: a battle between three treatments for patients with localized prostate cancer
